Johnson & Johnson (JNJ)vsProtalix Biotherapeutics Inc (PLX)
JNJ
Johnson & Johnson
$266.19
-1.62%
HEALTHCARE · Cap: $657.68B
PLX
Protalix Biotherapeutics Inc
$2.56
-1.16%
HEALTHCARE · Cap: $208.68M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 123115% more annual revenue ($99.33B vs $80.62M). PLX leads profitability with a 23.5% profit margin vs 16.2%. PLX trades at a lower P/E of 11.3x. PLX earns a higher WallStSmart Score of 66/100 (B-).
JNJ
Buy54
out of 100
Grade: C-
PLX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-89.3%
Fair Value
$144.28
Current Price
$266.19
$121.91 premium
Intrinsic value data unavailable for PLX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Attractively priced relative to earnings
Earnings expanding 2241.0% YoY
Every $100 of equity generates 23 in profit
Keeps 24 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 95.9%
Smaller company, higher risk/reward
Weak financial health signals
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bull Case : PLX
The strongest argument for PLX centers on P/E Ratio, EPS Growth, Return on Equity. Profitability is solid with margins at 23.5% and operating margin at 23.5%. Revenue growth of 27.1% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are Piotroski F-Score, PEG Ratio, P/E Ratio. A P/E of 41.5x leaves little room for execution misses.
Bear Case : PLX
The primary concerns for PLX are Market Cap, Piotroski F-Score, Free Cash Flow.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PLX is a growth play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.21 — expect wider price swings.
PLX is growing revenue faster at 27.1% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
PLX scores higher overall (66/100 vs 54/100), backed by strong 23.5% margins and 27.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Protalix Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?